Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-27. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Plasmin is inactivated by proteins such as α2-macroglobulin and α2-antiplasmin. The primary protein responsible for plasmin inhibition is the α2-antiplasmin which is a serpin protein. The C-terminal of the α2-antiplasmin binds plasminogen Kringle domains via lysine residues allowing for the inhibition of plasmin. Another method of plasmin inactivation involves the cleavage of an α2-macroglobulin at the bait region (a segment of the aM that is particularly susceptible to proteolytic cleavage) by plasmin. This initiates a conformational change such that the α2-macroglobulin collapses about the plasmin. In the resulting α2-macroglobulin-plasmin complex, the active site of plasmin is sterically shielded, thus substantially decreasing the plasmin's access to protein substrates. Two additional events occur as a consequence of bait region cleavage, namely (i) a h-cysteinyl-g-glutamyl thiol ester of the α2-macroglobulin becomes highly reactive and (ii) a major conformational change exposes a conserved COOH-terminal receptor binding domain. The exposure of this receptor binding domain allows the α2-macroglobulin protease complex to bind to clearance receptors and be removed from circulation. Plasmin can also be inhibited by inhibiting its activators, inactivating PAI-1 and PAI-2 blocks the production of tPA and uPA which subsequently stop the conversion of plasminogen into plasmin. Defects in the SERPINE1 gene cause deficiencies in PA1-2. PAI-2 is only detectable during pregnancy and lacks a signal sequence it is not secreted by the cell.
Chromatography can be used to determine the presence of substances in a sample, as different components in a mixture have different tendencies to adsorb onto the stationary phase or dissolve in the mobile phase. Thus, different components of the mixture move at different speeds. Different components of a mixture can therefore be identified by their respective Rƒ values, which is the ratio between the migration distance of the substance and the migration distance of the solvent front during chromatography. In combination with the instrumental methods, chromatography can be used in the quantitative determination of substances. There are different types of chromatography that differ from the media they use to separate the analyte and the sample. In thin-layer chromatography, the analyte mixture moves up and separates along the coated sheet under the volatile mobile phase. In gas chromatography, the gas phase separates the volatile analytes. A common method of chromatography using liquid as a mobile phase is high-performance liquid chromatography.
Any shorter time and the body would not be completely dehydrated; any longer, and the body would be too stiff to move into position for wrapping. The embalmers then washed the body again and wrapped it with linen bandages. The bandages were covered with a gum that modern research has shown is both a waterproofing agent and an antimicrobial agent. At this point, the body was given back to the family. These "perfect" mummies were then placed in human-shaped wooden cases. Wealthy people placed these wooden cases in stone sarcophagi that provided further protection. The family placed the sarcophagus in the tomb upright against the wall, according to Herodotus.
Sources: en.wikipedia.org
Mycorrhizal Associations: The Web Resource Comprehensive illustrations and lists of mycorrhizal and nonmycorrhizal plants and fungi Mycorrhizas – a successful symbiosis Biosafety research into genetically modified barley International Mycorrhiza Society International Mycorrhiza Society MycorWiki a portal concerned with the biology and ecology of ectomycorrhizal fungi and other forest fungi.
As an expansion pack for Half-Life, Blue Shift is a first-person shooter. The overall gameplay of Blue Shift does not significantly differ from that of Half-Life: players are required to navigate through the game's levels, fight hostile non-player characters and solve a variety of puzzles to advance. The game continues Half-Life's methods of an unbroken narrative. The player sees everything through the first-person perspective of the protagonist, and remains in control of the player character for almost all the game. Story events are conveyed through the use of scripted sequences rather than cut scenes. Progress through the game's world is continuous; although the game is divided up into chapters, the only significant pauses are when the game needs to load the next part of an environment. The player battles through the game alone, but is occasionally assisted by friendly non-player characters. Security guards and scientists will occasionally help the player in reaching new areas and convey relevant plot information. Blue Shift also includes a substantial section dedicated to keeping a major character in the story safe from enemy characters, and escorting him to a specific location. A selection of enemies from Half-Life populate the game, including alien creatures such as headcrabs and Vortigaunts. The player also encounters human opponents in the form of a detachment of US Marines who have been sent to eliminate the alien threat and silence any witnesses.
==== Stable isotope paleoaltimetry ==== The possibility of using water isotope depletion with elevation to reconstruct paleoaltimetry was demonstrated as early as the late 1960s, when Caltech geochemist Samuel Epstein tried to collect rainwater at different elevations in a single storm. The δ18O and δD lapse rates vary within -1 to -5‰/km and -10 to -40‰/km respectively, but can vary with locations and seasons, and are not exactly linear with altitude. One of the first studies in stable isotope paleoaltimetry demonstrated a meteoric water δD signature of -90 to -139‰ in fluid inclusions in quartz and adularia in an epithermal gold-silver deposit in Nevada, and suggested the applicability of stable isotopes in reconstruction of ancient topography in the Great Basin. The hydrogen and oxygen isotopes of hydrous silicate minerals have since then been used to reconstruct topographic histories in mountain ranges across the world, including the North American Cordillera, the Rocky Mountains, the Himalayas, the European Alps, and Southern Alps in New Zealand. Lab experiments with clay minerals have shown that the hydrogen and oxygen isotope compositions are relatively resistant to alteration at moderate temperature (<100°C), and can preserve the original meteoric water signal. One important effect of mountain ranges on rainfall stable isotopes is the rain shadow effect, in which an isotopic depletion happens in precipitation on the leeward side compared to the windward side.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.